Winning Stock Forecast: Top Performers In The Long (AMD) & Short (PTLA) Position After 3 Months

Winning AMD & PTLA Forecast

3 months ago, I Know First’s predictive algorithm conducted a forecast that would predict the success of the top stock picks of both bullish and bearish positions. For the long positions, the largest growth was registered by AMD with a return of 61.74%. The package itself which consisted of 5 overall picks in the long position, had an overall average return of 19.20%, providing a premium of 14.68% over the SP500’s return of 4.52%. The best performance in the short position came from PTLA which registered a return of 40.77%. With regards to the forecasted stocks at the

Read More

Winning Stocks Forecast: CUV.AX & YOW.AX bring highest returns from Australian stock market

Winning Stocks Forecast

Clinuvel Pharmaceuticals Limited (CUV.AX)

Source: biotech-capital.com

Over the past month Clinuvel Pharmaceuticals Limited (CUV.AX) saw a rise of 49.19% this marks it as the biggest earner within Australian Stock as I Know First predicted. This surge can be attributed to the anticipated FDA approval for its drug SCENESSE® a photo-protective drug used to treat a rare condition known as targeting erythropoietic protoporphyria (EPP). SCENESSE® is already approved by the EU in 2014 and was available from 2016 across Europe. In the first half of FY18, Clinuvel had revenue of just $7 million, enough to generate

Read More

Winning AMD & DDD Stock Forecast: The Biggest Of Tech Giants After Three Months

Winning AMD Stock Forecast

(By AMD via Wikimedia Commons)

In conjunction with I Know First’s 3 month algorithmic forecast, the top earner was AMD. The chipmakers’ saw increases of 106.35% at the conclusion of those months. The company that was once in big trouble has been on quite an incline. For 2018, AMD announced Q1 earnings of $1.65 billion, exceeding that with Q2 earnings of $1.76 billion. After increases in quality product, they are once again giving competitors NVDA and INTC

Read More

Winning Stock Forecast: Acadia, Protalix Bring Big Returns In The BioTech Space

ACAD Winning Stock Forecast

By Pöllö -commons.wikimedia.org

This week ACAD saw a 52.38% jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. Before this week, ACAD’s shares have been under pressure from what turned out to be an inaccurate report from CNN. Acadia Pharmaceuticals is again bringing in impressive returns. The drug under fire was Nuplazid. The FDA only recently discarded these allegations to be untrue. Nuplazid made up $57.1 million in sales Q2 for ACAD, an 18% increase from the first quarter. Sales of the drug are increasing 87% year over year. The

Read More

Winning AOBC Stock Forecast: American Outdoor Brands Corporation Aiming High And Reaching Their Target

Winning AOBC Stock Forecast

(Source: Flickr)

American Outdoor Brands Corporation (AOBC) has seen a large surge of success over the past couple of weeks. After seeing a 84% decline in their net income in 2018, coming down to $20 million. Firearm sales which are the core of the brand (AOBC also being known as the iconic arms brand Smith & Wesson), were down 41.9%. The decline in gun sales began with a push for tighter gun control laws in America, and took a steeper drop around election time. However, sales are once again looking to be on a healthy incline. It should be noted that the company also expanded out of

Read More

Winning FOSL Stock Forecast: Fossil Group Restructuring Plan Making The Right Plays In The Wearables Space

Winning FOSL Stock Forecast

“The introduction of smartwatches has had a huge impact on this category and it’s disrupted us in a really exciting way, We look at this as a new opportunity to grow the wrist.”

– Steve Evans, EVP Fossil Group

(Source: By Fossil Group (https://www.fossilgroup.com/) [Public domain], via Wikimedia Commons)

Although FOSL did not do well in its previous earnings reports, the outlook is quite positive for the company as it continues it restructure plan called the New World Fossil. They have been closing unprofitable stores and products recently

Read More

Winning ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc Jumped Up 87.41% In 3 Months After Strong Buy Prediction

“The ARO-AAT Phase 1 study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM™, platform. We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

– Chris Anzalone, Ph.D., President and CEO of Arrowhead

(Source: Wikimedia Commons)

For three months since March 28th, 2018, Arrowhead Pharmaceuticals Inc (NYSE: ARWR) has gained 87.41%, becoming one of the most profitable stocks in pharmaceuticals industry. The success

Read More

Pages:1234»